Whether to make decisions "on the fly" regarding treatment for SARS-CoV-2 infection

Abril López de Medrano, V.; Merino de Lucas, E.; Salavert Lletí, M.

doi:10.1016/j.rceng.2020.07.002

array:23 ["pii" => "S2254887420300813" "issn" => "22548874" "doi" => "10.1016/j.rceng.2020.07.002" "estado" => "S300" "fechaPublicacion" => "2020-10-01" "aid" => "1832" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "copyrightAnyo" => "2020" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2020;220:461-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0014256520301107" "issn" => "00142565" "doi" => "10.1016/j.rce.2020.04.004" "estado" => "S300" "fechaPublicacion" => "2020-10-01" "aid" => "1832" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2020;220:461-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "Correspondencia" "titulo" => "Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infección por SARS-CoV-2" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "461" "paginaFinal" => "462" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Whether to make decisions «on the fly» regarding treatment for SARS-CoV-2 infection" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "V. Abril López de Medrano, E. Merino de Lucas, M. Salavert Lletí" "autores" => array:3 [ 0 => array:2 [ "nombre" => "V." "apellidos" => "Abril López de Medrano" ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Merino de Lucas" ] 2 => array:2 [ "nombre" => "M." "apellidos" => "Salavert Lletí" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2254887420300813" "doi" => "10.1016/j.rceng.2020.07.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887420300813?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256520301107?idApp=WRCEE" "url" => "/00142565/0000022000000007/v1_202009260731/S0014256520301107/v1_202009260731/es/main.assets" ] ] "itemAnterior" => array:19 [ "pii" => "S2254887420300746" "issn" => "22548874" "doi" => "10.1016/j.rceng.2020.05.007" "estado" => "S300" "fechaPublicacion" => "2020-10-01" "aid" => "1861" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2020;220:459-61" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Correspondence" "titulo" => "Pulmonary embolism and COVID-19: A paradigm change" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "459" "paginaFinal" => "461" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tromboembolismo pulmonar y COVID-19: un cambio de paradigma" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Franco-Moreno, N. Muñoz-Rivas, B. Mestre-Gómez, J. Torres-Macho" "autores" => array:4 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Franco-Moreno" ] 1 => array:2 [ "nombre" => "N." "apellidos" => "Muñoz-Rivas" ] 2 => array:2 [ "nombre" => "B." "apellidos" => "Mestre-Gómez" ] 3 => array:2 [ "nombre" => "J." "apellidos" => "Torres-Macho" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0014256520301405" "doi" => "10.1016/j.rce.2020.05.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256520301405?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887420300746?idApp=WRCEE" "url" => "/22548874/0000022000000007/v2_202010040643/S2254887420300746/v2_202010040643/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Correspondence" "titulo" => "Whether to make decisions "on the fly" regarding treatment for SARS-CoV-2 infection" "tieneTextoCompleto" => true "saludo" => "Dear Director," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "461" "paginaFinal" => "462" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "V. Abril López de Medrano, E. Merino de Lucas, M. Salavert Lletí" "autores" => array:3 [ 0 => array:4 [ "nombre" => "V." "apellidos" => "Abril López de Medrano" "email" => array:1 [ 0 => "vicente.abril.lopezdemedrano@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "E." "apellidos" => "Merino de Lucas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "M." "apellidos" => "Salavert Lletí" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Consorcio Hospital General Universitario de Valencia, Valencia, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Hospital General Universitario de Alicante, Alicante, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Hospital Universitario y Politécnico La Fe, Valencia, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infección por SARS-CoV-2" ] ] "textoCompleto" => "The outbreak of the COVID-19 pandemic is a challenge of enormous dimensions for healthcare professionals, public health, and politicians.As of April 5, 2020, official figures revealed that there were 135,032 people infected, 13,055 deaths, and 59,662 patients hospitalized (<a href="https://covid19.isciii.es/">https://covid19.isciii.es/</a>). We lived through convulsive days in which treatment protocols for COVID-19 infection were modified practically daily based on new evidence and the need to optimize the scarce therapeutic arsenal available.Just three weeks ago, we learned the results of a clinical trial that compared lopinavir/ritonavir to supportive treatment in severe patients hospitalized with COVID-19 infection whose primary outcome was time until clinical improvement.<a class="elsevierStyleCrossRef" href="#bib0005">1</a> The poor overall results in terms of clinical response and mortality led, in just a few hours, to a rare wave of pessimism among the groups of professionals in charge of making decisions in many hospitals. This was reflected in heated discussions via WhatsApp and other forums, leading to the abrupt removal of lopinavir/ritonavir from the treatment protocols of several large centers in our country.Nevertheless, the result of the information from a trial such as that one must be taken cautiously and analyzed with a critical, rigorous eye. The work suffers from various methodological problems in the design and in patient recruitment related to the urgent nature of the work. The authors themselves recognize these aspects in the discussion. Patient assignment was not blind and the desirable placebo control was not able to be established for patients who did not receive the drug in said study. Likewise, plasma levels of lopinavir/ritonavir were not able to be determined and could have been compromised in critical patients.On the other hand, the study lacks power for outcomes that are secondary in the design, but which are important, such as mortality. Assuming the same premises as for the principal variable, between 200 and 860 additional patients would have been needed in each arm to demonstrate differences. In addition, although the overall benefit was weak, a close reading allows for observing how the use of lopinavir/ritonavir could point towards a trend in mortality reduction if it is used in the first 12 days. Among patients treated earlier, the primary objective was indeed achieved, with respective mortality of 15% versus 27% in each arm. What’s more, the other secondary aims, such as a stay in the intensive care unit (5 days of difference) and the percentage of patients who developed ARDS (12% versus 24%), were also improved.In our opinion, the fundamental issue is that patients were treated too late (median of 13 days from onset of symptoms) and in monotherapy. Therefore, although it did not achieve the primary aim, the results indicate that the treated group could progress better. Therefore, it remains to be determined if the use of lopinavir/ritonavir in the earliest phases and/or in combination with other potentially active drugs would benefit patients or not.Nevertheless, we are aware of the lack of trust that protease inhibitors and their limited in vitro activity generate and in their clinical efficacy in this novel coronavirus and in others (SARS-CoV, MERS-CoV).<a class="elsevierStyleCrossRefs" href="#bib0010">2,3</a> The controversial results of this study had already in part been anticipated in another Chinese study,<a class="elsevierStyleCrossRef" href="#bib0020">4</a> which did not demonstrate a benefit to treatment with lopinavir/ritonavir and abidol. Furthermore, Janssen has reported unpublished data on the inefficacy of darunavir/cobicistat in the treatment of 30 patients with COVID-19.<a class="elsevierStyleCrossRef" href="#bib0025">5</a>Even so, while awaiting new evidence or consolidated alternative therapies, it seems prudent to continue using the optimize form of the few drugs we do have available.In catastrophic times, it is important to keep a cool head and even keel when it comes to making decisions that may determine a patient’s prognosis." "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Abril López de Medrano V, Merino de Lucas E, Salavert Lletí M. Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infección por SARS-CoV-2. Rev Clin Esp. 2020;220:461–462." ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trial of lopinavir-ritonavir in adults hospitalized with severe covid-19" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Cao" 1 => "Y. Wang" 2 => "D. Wen" 3 => "W. Liu" 4 => "J. Wang" 5 => "G. Fan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa2001282" "Revista" => array:3 [ "tituloSerie" => "N Engl J Med" "fecha" => "2020" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32222134" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "V.C.C. Cheng" 1 => "S.K.P. Lau" 2 => "P.C.Y. Woo" 3 => "K.Y. Yuen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Microbiol Rev" "fecha" => "2007" "volumen" => "20" "paginaInicial" => "660" "paginaFinal" => "694" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "From SARS to MERS, thrusting coronaviruses into the spotlight" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Z. Song" 1 => "Y. Xu" 2 => "L. Bao" 3 => "L. Zhang" 4 => "P. Yu" 5 => "Y. Qu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/v11010059" "Revista" => array:6 [ "tituloSerie" => "Viruses" "fecha" => "2019" "volumen" => "11" "paginaInicial" => "E59" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30646565" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1878875018313068" "estado" => "S300" "issn" => "18788750" ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Jun" 1 => "L. Yun" 2 => "X. Xiuhong" 3 => "L. Ping" 4 => "L. Feng" 5 => "L. Tao" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3760/cma.j.cn311365-20200210-00050" "Revista" => array:3 [ "tituloSerie" => "Chin J Infect Dis" "fecha" => "2020" "volumen" => "38" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Results from a single center, open label, randomized, and controlled trial conducted at Shanghai Public Health Clinical Center (SPHCC) of darunavir and cobicistat (DRV/c) in treating laboratory-confirmed 30 COVID-19 patients showed that DRV/c was not effective. Available in: <a target="_blank" href="https://www.jnj.com/lack-of-evidence-to-support-darunavir-based-hiv-treatments-for-coronavirus">https://www.jnj.com/lack-of-evidence-to-support-darunavir-based-hiv-treatments-for-coronavirus</a>. [Accessed 6 April 2020]." ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/22548874/0000022000000007/v2_202010040643/S2254887420300813/v2_202010040643/en/main.assets" "Apartado" => array:4 [ "identificador" => "71813" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Correspondence" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22548874/0000022000000007/v2_202010040643/S2254887420300813/v2_202010040643/en/main.pdf?idApp=WRCEE&text.app=https://revclinesp.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887420300813?idApp=WRCEE"]

Revista Clínica Española (English Edition)

ISSN: 2254-8874

Revista Clínica Española published its first issue in 1940 and is the body of expression of the Spanish Society of Internal Medicine (SEMI).
The journal fully endorses the goals of updating knowledge and facilitating the acquisition of key developments in internal medicine applied to clinical practice. Revista Clínica Española is subject to a thorough double blind review of the received articles written in Spanish or English. Ten issues are published each year, including mostly originals, reviews and consensus documents.

Indexed in:

Current Contents / Clinical Medicine , JCR / SCI-Expanded, Index Medicus / Medline y Excerpta Medica / EMBASE

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

2.3

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

0.7

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.162

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.211

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Vol. 220. Issue 7.

Pages 461-462 (October 2020)

Lee este artículo en Español

Export reference

Download PDF

Article

These are the options to access the full texts of the publication Revista Clínica Española (English Edition)

Member of the society

Subscriber

Contact

Member

Si es usted socio de FESEMI siga los siguientes pasos:

Diríjase desde aquí a la web de la >>>FESEMI<<< e inicie sesión mediante el formulario que se encuentra en la barra superior, pulsando sobre el candado.